Gilead Sciences, Inc. $GILD Position Lifted by Summit Global Investments

Summit Global Investments raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 41.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,549 shares of the biopharmaceutical company’s stock after buying an additional 4,837 shares during the quarter. Summit Global Investments’ holdings in Gilead Sciences were worth $2,467,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in GILD. PFS Partners LLC boosted its holdings in Gilead Sciences by 101.1% in the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 96 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $25,000. Laurel Wealth Advisors LLC purchased a new stake in Gilead Sciences in the third quarter worth approximately $29,000. Kimelman & Baird LLC purchased a new stake in Gilead Sciences during the 2nd quarter valued at $25,000. Finally, Toth Financial Advisory Corp lifted its holdings in shares of Gilead Sciences by 85.5% during the 3rd quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 100 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

Gilead Sciences Trading Up 3.1%

Shares of GILD opened at $170.68 on Friday. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The company has a market cap of $211.63 billion, a P/E ratio of -54.01 and a beta of 0.31. Gilead Sciences, Inc. has a twelve month low of $114.02 and a twelve month high of $175.65. The company’s fifty day simple moving average is $150.87 and its 200-day simple moving average is $139.79.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.70% and a negative net margin of 12.47%. The business had revenue of $8.30 billion during the quarter, compared to analyst estimates of $7.81 billion. During the same quarter in the previous year, the business earned $2.47 earnings per share. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. As a group, analysts expect that Gilead Sciences, Inc. will post -1.03 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a $0.82 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. Gilead Sciences’s payout ratio is presently -103.80%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the sale, the insider directly owned 113,684 shares in the company, valued at approximately $17,759,714.48. This represents a 2.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the transaction, the director owned 10,066 shares in the company, valued at approximately $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 111,000 shares of company stock worth $15,877,860. 0.30% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have issued reports on GILD shares. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Wells Fargo & Company increased their price target on Gilead Sciences from $165.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday. BMO Capital Markets reaffirmed an “outperform” rating and set a $184.00 price objective on shares of Gilead Sciences in a report on Friday. Scotiabank lifted their target price on Gilead Sciences from $177.00 to $200.00 and gave the stock a “sector outperform” rating in a report on Friday. Finally, HSBC raised their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $169.19.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.